The week in health tech, explained in plain English.Get the free newsletter →
October 24, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

Monument Health Names New General Counsel in Executive Shuffle

Monument Health, the Rapid City, South Dakota-based system, has added two leaders to its executive team, effective June 8. Paula McInerney-Hall was promoted to general counsel after serving as associate general counsel, according to a June 5 release reported by Becker's Hospital Review. In the role she becomes the system's chief legal adviser, leading on legal and compliance matters.

The moves reflect a broader pattern across regional health systems, which are deepening their executive benches to handle rising regulatory, contracting, and compliance demands. Promoting internally for a top legal seat signals continuity and institutional knowledge at a time when hospitals face mounting scrutiny on pricing, labor, and care delivery.

For operators, leadership stability at smaller and mid-sized systems matters as much as it does at large urban networks. Monument Health serves a largely rural population across western South Dakota, where access and recruitment challenges make seasoned, locally grounded leadership especially valuable.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.